Tetra Tx Initiates PIIb/III Studies of BPN14770 in Fragile X Syndrome
12 Jul 2022 //
BUSINESSWIRE
Tetra Therapeutics Announces Retirement of Mark Gurney
23 Jul 2021 //
BUSINESSWIRE
Tetra Announces Positive Topline Results from Phase 2 Study of BPN14770
02 Nov 2020 //
BIOSPACE
Tetra Announces Positive Topline Results from Phase 2 Study of BPN14770
02 Nov 2020 //
BUSINESSWIRE